Bristol Myers Squibb Reports Five-Year Survival Data for Opdivo in Gastric Cancer

Bristol Myers Squibb today presented five-year overall survival data from the CheckMate-649 trial evaluating Opdivo (nivolumab) plus chemotherapy in patients with previously untreated advanced gastric cancer. The data showed that Opdivo plus chemotherapy continued to demonstrate a survival benefit over chemotherapy alone at five years.